AARTIDRUGS2024-04-012024-06-30 AARTIDRUGS2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member AARTIDRUGS2024-06-30 AARTIDRUGS2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AARTIDRUGS2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member AARTIDRUGS2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524348 AARTIDRUGS NOTLISTED Aarti Drugs Limited Equity 2024-04-01 2025-03-31 2024-07-26 2024-07-19 INR Lakhs First quarter 12:00:00 17:15:00 2024-07-26 2024-07-26 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Audited Consolidated 5553400000.00 11100000.00 5564500000.00 3477900000.00 175400000.00 -55100000.00 264300000.00 87100000.00 133800000.00 1041300000.00 5124700000.00 439800000.00 0.00 439800000.00 100200000.00 6900000.00 107100000.00 0.00 332700000.00 0.00 0.00 0.00 0.00 332700000.00 4200000.00 336900000.00 332400000.00 289000.00 336400000.00 499000.00 919400000.00 10 3.62 3.62 0.00 0.00 3.62 3.62 0.00 0.00 0.00 1. The above results for the quarter ended 30th June, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 26th July, 2024.  2. Production at Unit N-198 located at Tarapur was temporarily disrupted due to a fire incident that took place on 17th June 2024. This unit has now become operational from 9th July 2024. The said Unit has adequate insurance coverage and necessary intimation to insurance company has already been given. According to management there is no material financial impact. Further the company is in the process of assessing & filing the final insurance claim with Insurance company and hence no financial impact has been considered in the aforesaid results for the quarter ended June 2024. 3.Based on Voluntary Closure Direction Order received from Maharashtra Pollution Control Board (MPCB), the Company has stopped production of a particular product from 18th July 2024 (i.e. after the close of Q1) on account of Bromine Gas Leakage which took place in factory premises at unit T-150 located at Tarapur. The manufacturing of other products at the unit T-150 has remained operational. According to the Management's assessment, there is no material impact since the said product is used for captive consumption and the Company has enough inventory of the same 4. Company has only one business segment i.e. pharmaceuticals. 5.Figures for the previous Quarter have been regrouped or rearranged wherever necessary. 6. The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.co.in and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors FOR AARTI DRUGS LIMITED PRAKASH M. PATIL CHAIRMAN, MANAGING DIRECTOR & CEO DIN: 00005618 Place: Mumbai Date: 26th July 2024 Other expenses 1041300000.00 Fair value changes on Investments, net 0.00 Remeasurement of defined benefit Liabiliy/Assets, net 0.00 Remeasurement of defined benefit Liabiliy/Assets, net 4200000.00 4200000.00 0.00 0.00